
Mosquitoes bite! 5 tips for making yourself less attractive to them
(CNN) — For summertime beachgoers, the threat of sharks may loom large, but nature's deadliest predator is actually much smaller.
The tiny mosquito is not only a warm-weather nuisance but also wears the crown for 'No. 1 killer of humanity across our existence,' according to historian Dr. Timothy C. Winegard. The predatory insect takes more than 1 million lives each year by transmitting lethal diseases. Sharks, meanwhile, are estimated to have a kill streak orders of magnitude smaller, at fewer than 10 people per year.
Where humans go, mosquitoes have followed. Their itchy bites and the disease-causing pathogens they carry are infamous, and the insects are also responsible for driving many of humanity's most essential turning points throughout history, said Winegard, author of 'The Mosquito: A Human History of Our Deadliest Predator.'
'Malaria and yellow fever (have shaped) our historical journey from our hominid ancestral evolution … right to present day,' Winegard told CNN Chief Medical Correspondent Dr. Sanjay Gupta recently on his podcast, Chasing Life.
Winegard, an associate professor of history at Colorado Mesa University, got the initial idea for his best-selling book from his dad's interest in malaria.
The wee pest didn't intrigue Winegard too much at first. 'I kind of disparaged him and said, 'Sure, dad, I'll write a book on mosquitoes,'' he recalled. But once Winegard began going down the rabbit hole of mosquito-borne pathogens' impact on humanity — including, but not limited to malaria, Zika virus, dengue fever, yellow fever, chikungunya and West Nile virus — he couldn't stop.
The mosquito's impact on history is still deeply felt in the present. More than half a million people die of malaria alone each year, and disease-heavy regions have suffered financially as a result. 'Northern Hemisphere countries don't have endemic malaria, (so) they're able to develop more affluent economies because they're not continuously suffering from malaria,' Winegard said.
You can listen to the full episode here.
Humans have been battling mosquitoes for millennia, and amid the season's summer peak in the Northern Hemisphere, Winegard offered some insight into how you can keep them away this summer.
'Eighty-five percent of what makes you alluring or less alluring to mosquitoes is prewired in your genetic circuit board,' according to Winegard. However, there are a few ways you can manage mosquitoes. He has these five tips.
Booze makes it easier for mosquitoes to see you, Winegard said.
Mosquitoes hunt by sight, but they don't see the world like people do. The predatory insects employ thermal, or infrared, vision. 'They see heat signatures,' Winegard noted.
'Consuming alcohol raises your body temperature,' he explained over email, 'which make(s) you an identifiable heat signature for your soon-to-be tormentor.'
So, maybe reach for a refreshing glass of water or lemonade instead of that beer.
In addition to using heat-based vision, mosquitoes hunt down humans primarily through smell.
Winegard said mosquitoes 'can smell carbon dioxide from over 200 feet (60 meters) away.'
'So if you're exercising or breathing heavily, they'll smell that and be attracted to it,' Winegard told Gupta.
And just like alcohol, high CO2 emissions make detecting heat signatures easier for mosquitoes, so Winegard recommends keeping yourself as cool as possible.
This applies to your wardrobe, too. 'Dark clothes retain relatively more heat,' he said, so it's best to opt for lighter-colored, long-sleeved attire to keep mosquitoes at bay.
Applying insect repellent is the gold standard for mosquito management, but if you're not careful when applying it, you can leave yourself vulnerable to bites.
'I know people who lather themselves in it, but they miss this little spot on the back of their calf and she'll find the chink in our armor,' Winegard told Gupta, referring to the female mosquito, who is the bloodsucking hunter.
Mosquito repellent isn't like perfume, in which a few spritzes can cover your whole body. If you're spraying, make sure to be thorough.
'DEET (a chemical repellent) is still the gold standard, while oil of lemon eucalyptus is a plant-derived option,' Winegard said.
For an added boost of security, he noted some clothes come pretreated with a mosquito-targeted insecticide called permethrin.
Pool days and cool drinks outdoors offer a respite from the heat for humans, but they are equally as attractive to mosquitoes. Female mosquitoes lay their eggs in still water — and they don't need much.
'From a pond or stream to a minuscule collection in the bottom of an old container, used tire, or backyard toy — even a bottle cap full — any will suffice,' Winegard said via email. Even waterlogged soil is enough for mom-to-be mosquitoes to lay their eggs in, he added.
Winegard recommended eliminating standing water around your home and yard to keep potential mosquito breeding grounds to a minimum.
Another way to fight the swarms this summer is to consider skipping a shower or two.
'It's better to be stinky!' Winegard said. 'Being pungently rancid is a good thing, for it increases bacterial levels on the skin, which makes you less alluring to mosquitoes.'
While this may offend others, Winegard says to skip the scented products: Deodorants, soaps and other applied fragrances are all enticing to mosquitoes.
The one exception is your feet. 'Clean your feet,' he told Gupta. 'The bacteria on our feet, which is the same one that ripens a lot of cheeses, is an aphrodisiac to mosquitoes.'
Winegard noted that this is the reason many of us get bitten around our ankles and feet. 'So, wash your feet!' he urged.
Mosquitoes don't care about most personal characteristics you can objectively see.
'There is absolutely no truth to the persistent myths that mosquitoes fancy females over males, that they prefer blondes and redheads over those with darker hair, or that the darker or more leathery your skin, the safer you are from her bite,' Winegard said.
But he noted that 'she does play favorites and feasts on some more than others.'
What might entice a mosquito? 'Blood type O seems to be the vintage of choice over types A and B or their blend,' he said. 'People with blood type O get bitten twice as often as those with type A, with type B falling somewhere in between.'
The creators of the 1998 movie 'A Bug's Life,' he noted, must have 'done their homework when portraying a tipsy mosquito ordering a 'Bloody Mary, O-positive.''
Maybe it's a mosquito's world, Winegard suggests, and people are just living in it.
We hope these five tips help you keep mosquitoes at bay. Listen to the full episode here. And join us next week for a new episode of the Chasing Life podcast.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Medscape
15 minutes ago
- Medscape
Neoadjuvant vs Adjuvant Immunotherapy in Colon Cancer
The results of the phase III ATOMIC trial fired another volley in the ongoing debate over adjuvant vs neoadjuvant immunotherapy for patients with locally advanced colon cancer. But experts are divided about which treatment plan is the best. Adjuvant immunotherapy plus chemotherapy has yet to square off against neoadjuvant immunotherapy in a head-to-head trial. Even if that trial doesn't happen, post hoc analyses of ATOMIC and the neoadjuvant NICHE-2 studies may clarify whether a one-size-fits-all approach is appropriate and help determine which patients benefit more from one approach over the other, according to Christopher Lieu, MD, an investigator in the ATOMIC study. The ATOMIC study showed that adding adjuvant immunotherapy to standard-of-care chemotherapy following resection reduced the risk for disease recurrence or death by 50% compared with chemotherapy alone in the 355 patients with stage III colon cancer with mismatch repair deficiency (dMMR), who received adjuvant atezolizumab along with fluorouracil, leucovorin, and oxaliplatin (FOLFOX) chemotherapy, providing those in the pro-adjuvant camp with important data. In addition, 3-year disease-free survival (DFS) was 86.4% with the combination compared with 76.6% with chemotherapy alone. The results of this trial were presented at the American Society of Clinical Oncology (ASCO) 2025. 'These data established this combination as a new standard treatment for patients with stage III colon cancer and deficient mismatch repair,' said study author Frank A. Sinicrope, MD, during a press conference at the meeting. 'We regard this as a highly impactful study that will change clinical practice, and it actually represents the first immunotherapy adjuvant study in colon cancer.' In NICHE-2, patients were given neoadjuvant ipilimumab or nivolumab followed by surgical resection. At 3 years, 100% of all 111 patients treated with ipilimumab and nivolumab prior to surgery were recurrence-free, according to a presentation at last year's annual meeting of the European Society for Medical Oncology (ESMO). The DFS beat the prespecified success threshold of 93%. Adding Immunotherapy The standard treatment for stage III colon cancer, regardless of dMMR status, is surgical resection followed by FOLFOX chemotherapy. However, about 15% of patients with stage III colon cancer have dMMR and display resistance to chemotherapy, providing a rationale for adding immunotherapies to standard treatment. 'These tumors are unable to repair their DNA and therefore accumulate mutations that trigger an immune response that is ineffective due to immune checkpoint proteins. Therefore, the use of immune checkpoint inhibitors is very attractive in this setting,' Sinicrope said during the press briefing. Sinicrope is professor of medicine and oncology, and coleader of the Gastrointestinal Cancer Program at Mayo Clinic in Rochester, Minnesota. Adjuvant Immunotherapy The ATOMIC trial is significant because it demonstrates improved DFS with the addition of immunotherapy to standard chemotherapy treatment, improving outcomes for patients with this type of locally advanced cancer over standard care. There are several rationales for adding immunotherapy following surgical resection. For example, staging relies on tumor appearance on CT scan, said Lieu, who is the codirector of Gastrointestinal Medical Oncology at the University of Colorado Cancer Center in Aurora, Colorado. There are patients with dMMR or microsatellite instability-high (MSI-H) colon cancer that appear to have stage I or II disease on their CT scan. 'In those patients, starting with immunotherapy first may not be the best idea because after a stage I or II colon cancer is resected, they don't require any further therapy because of the low risk of recurrence,' he said. 'If you think it is an early-stage cancer based of radiographic findings, you could cut out the cancer and then only offer chemotherapy and immunotherapy if it is unexpectedly stage III. I think that there's certainly rationale for that,' he continued. Other arguments for adjuvant immune checkpoint inhibitors, like atezolizumab, with chemotherapy include synergy between cytotoxic and immune mechanisms and systemic insurance against micrometastatic spread. It also avoids the potential for rare immune complications from upfront immunotherapy that could delay surgery. 'I don't think that [giving all patients neoadjuvant treatment] is the answer. If you think that they have stage I or stage II colon cancer at the beginning, then you might end up hurting them with upfront immunotherapy,' said Lieu. Neoadjuvant Immunotherapy The standard treatment for stage III colon cancer, regardless of dMMR status, is surgical resection followed by chemotherapy, FOLFOX and capecitabine and oxaliplatin (CAPOX) are two of the most common regimens. However, chemotherapy can be hard on patients, making neoadjuvant immunotherapy that can reduce or eliminate the need for post-surgical chemotherapy very attractive. The data from the NICHE-2 trial support the efficacy of neoadjuvant immunotherapy. 'The data strongly suggest that neoadjuvant immunotherapy is better than adjuvant immunotherapy and that chemotherapy for dMMR colorectal cancer has limited activity,' said Michael J. Overman, MD, Associate Vice President of Research for the MD Anderson Cancer Network in Houston, in an interview. 'Thus, I am a believer that neoadjuvant is the preferred approach for dMMR localized cancers.' Lieu said neoadjuvant immunotherapy might be more appropriate for more aggressive disease. 'What we discuss in our multidisciplinary clinic is that if these patients are diagnosed prior to surgery and particularly if they have aggressive features…those are some of the patients that I really would consider for neoadjuvant therapy,' he said. 'While it's high-risk disease, there could be some benefit to down-staging the patient, so that there isn't a positive margin. If there's pathologic complete response…and you don't have to give adjuvant chemotherapy, most people would consider that to be a win.' Overman noted that 'a big open area relates to whether the goal of neoadjuvant therapy should be operation or no operation. Likely both approaches can be done and that would be up to patient and physician.' However, 'with a nonoperative approach, we still have unknowns regarding disease assessment and surveillance for neoadjuvant therapy.' Patient-Specific Care In the absence of data from a head-to-head trial of the two approaches, a patient-specific approach may be the appropriate strategy, Lieu suggested. 'If I had a take home message, it's just that it's clear that these patients really require multidisciplinary discussion before an operation,' he said. Molecular testing has an important role to play as well, said Lieu. 'It speaks to the importance of doing biomarker testing for MMR, MSI, or both. Alarm bells should be ringing as soon as [either or both come] back positive; it should make everyone think for a second and make sure we have the right plan for the right patients.' Sinicrope reported several relationships, including with Eli Lilly, Guardant Health, Roche Holdings AG, Ventana Medical Systems, and Woven Health Collective. Lieu reported relationships with Amgen and Genentech.


Fast Company
15 minutes ago
- Fast Company
Why urban designers should think like doctors
What if buildings and neighborhoods were planned with health and climate risks in mind, just like businesses use financial data to guide their decisions? What if public health and real estate weren't at odds, but instead coauthors of a healthier, more equitable urban future? That's the bold premise of Architectural Epidemiology, a new book that offers a radical rethinking of the relationship between place and health. Written by architect and public health expert Adele Houghton and Dr. Carlos Castillo-Salgado, an epidemiologist, the book introduces a place-based framework for aligning real estate investment with public health goals—using the tools of epidemiology to guide design decisions that affect buildings and the way they engage the surrounding city. At its core, architectural epidemiology is not a metaphor. It's a methodology. Diagnosing places like patients Just as a doctor might diagnose a patient based on symptoms and environmental exposures, Houghton and Castillo-Salgado's framework helps designers, developers, and policymakers diagnose the health of a place. The process begins by gathering publicly available health and climate data—rates of asthma, heat exposure, housing-cost burden, chronic illness, and more—and dialing into the specific needs of any real estate project boundary. These place-based insights then inform customized development strategies tailored to local needs. This isn't a one-size-fits-all checklist. It's a locally calibrated, equity-centered approach that asks: What are the most urgent public health and climate concerns in this neighborhood? And how can this project become part of the solution? Two case studies from the book, one in the South Bronx and another in East London, show how this approach plays out in the real world. Toxic infrastructure to health-first housing The South Bronx is one of New York City's most environmentally burdened neighborhoods. Residents face compounding public health concerns, including high rates of obesity, diabetes, heart disease, and pediatric asthma—conditions tied directly to chronic exposure to air pollution, extreme heat, and poor housing conditions. Infrastructure like solid waste transfer stations, natural gas plants, and a daily flow of more than 750 diesel trucks has left a lasting environmental footprint. Three projects demonstrate how health-driven interventions play out in real life. Arbor House, a 124-unit LEED Platinum affordable housing development, took an indoor-focused strategy. With no regulatory leverage to reduce nearby traffic or emissions, the project team instead designed a protective shell: a high-performance building envelope, mechanical exhaust and ventilation systems, low-VOC materials, and a no-smoking policy. These features directly addressed local respiratory and cardiovascular risk data, providing a sanctuary of clean air in a polluted context. The Eltona, another LEED Platinum project by the same developer, built on these strategies but also benefited from its location within the Melrose Commons urban renewal zone. This area, guided by a community-authored plan, introduced pedestrian-prioritized streets and small green spaces to break up heat and pollution hot spots. This sort of coordinated planning can push health equity beyond the building envelope. The Peninsula represents an even bolder intervention: transforming a former juvenile detention center into a mixed-use anchor of community well-being. Once all phases are complete (anticipated in 2026), the project will deliver 740 units of affordable housing, a wellness center, daycare, supermarket, light industrial space, and a workforce development hub—all aligned with the long-standing Hunts Point Vision Plan. Created through a collaborative effort between local government and community groups, the plan calls for cleaner air, economic opportunity, and access to green space without displacing existing residents. This multiscalar transformation wouldn't have been possible without partnership. The development team committed to providing both affordable and middle-income housing, as well as commercial and industrial spaces aligned with local needs. The local government played a convening role, confronting outdated zoning and building codes to enable community-led regeneration. And community groups acted as watchdogs and visionaries—documenting health inequities, advocating for residents' needs, and ensuring decades of disinvestment didn't translate into displacement. From industrial blight to inclusive growth In East London's Hackney borough, Gillett Square shows how long-term, community-led urban design can build resilience without triggering displacement. Residents here also face elevated risks from exposure to traffic-related air pollution, unsafe pedestrian conditions, and mental health stressors, particularly among children and the elderly. Climate concerns such as extreme temperatures compound vulnerability, especially in a borough with high poverty rates and a large renter population. The project began in the 1980s as part of a broader, three-pronged effort to reduce crime, create economic opportunity for women- and minority-owned businesses, and preserve affordability in the face of rapidly rising property values. Organized by Hackney Co-operative Developments, a community interest company, this initiative has grown over 40 years into a model of place-based health equity. Unlike top-down redevelopment, the transformation of Gillett Square unfolded through continuous negotiation among residents, developers, and the local government. A former parking lot became the square itself. Adjacent buildings were renovated to create 30 affordable workspaces and 10 retail units prioritized for local startups and cultural groups. The existing street-facing storefronts remained intact, maintaining the character and economic rhythms of the block. During construction, current tenants were temporarily relocated—but not displaced—a rare feat in most urban redevelopment narratives. The built environment improvements weren't just aesthetic or economic. The renovated Bradbury Works building added insulation, operable windows, and improved ventilation to respond to extreme temperatures and indoor air quality concerns. It was also designed to accommodate a future rooftop solar array. Elsewhere on the square, an old factory became a jazz club. Another was converted into a mixed-use building with social housing and office space. Each adaptive reuse project layered with health-promoting elements such as natural light, passive ventilation, and energy efficiency. Importantly, these design moves responded to both immediate and long-term public health concerns identified in the architectural epidemiology framework: exposure to air pollution, heat vulnerability, mental health stressors, and pedestrian safety risks. The health situation analysis for the neighborhood emphasized the need for strategies that reduced the risk of obesity, mental health issues, and traffic-related injury, many of which were tackled by fine-grained, community-rooted design rather than by sweeping interventions. Gillett Square's evolution also depended on progressive land use policy and community engagement over time. The local government enabled critical rezonings: converting the parking lot into a plaza, allowing mixed-use development, and permitting the installation of small retail kiosks. The development team, operating as a nonprofit social enterprise, prioritized community interests. And community groups, many of which had been active in Hackney for decades, fought to ensure that the square's benefits didn't come at the expense of its existing residents. In a borough where 75% of residents are renters, and poverty rates among children and the elderly are among the highest in the U.K., the stakes of gentrification are high. Gillett Square proves that design can support resilience without fueling displacement—and that longevity, not speed, can be a hallmark of justice-oriented urban development. These case studies show that health equity can be the foundation, not a by-product, of urban development. By aligning investments with public health and climate data, Architectural Epidemiology offers a road map for building places that protect and uplift communities. This framework identifies community needs and guides community residents, developers, and designers to solutions that create value for both stakeholders and shareholders.

Wall Street Journal
16 minutes ago
- Wall Street Journal
The Medicare Pullback Is Here
Many seniors enjoy the perks that come with Medicare Advantage. But those extras—like dental coverage and free gym memberships—are being scaled back. Insurers are cutting benefits and exiting from unprofitable markets, and Wall Street is cheering them on. Once rewarded by investors for rapid expansion in the lucrative privatized Medicare program, companies are now being applauded for showing restraint amid rising medical costs and lower government payments.